Skip Main Navigation Links Jump to Footer

Scopus Preview

Current Cancer Drug TargetsVolume 16, Issue 3, 1 March 2016, Pages 226-237

Understanding cancer drug resistance by developing and studying resistant cell line models(Article)

  • aI3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
  • bCancer Drug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, 4200-465, Portugal
  • cInstitute for Biological Research “Sinisa Stankovic”, University of Belgrade, Bulevar Despota Stefana 142, Belgrade, 11060, Serbia
  • dDepartment of Biological Sciences, University of Porto, Porto, 4050-313, Portugal

Abstract

Despite the enormous number of anticancer drugs presently available in the clinic, treatment failure due to drug resistance is very frequent. The identification of mechanisms of resistance to different drugs is necessary, in order to identify ways to prevent and circumvent such resistance. Indeed, the identification of novel therapeutic targets to overcome cancer drug resistance remains one of the major challenges in drug discovery and development. The methods employed to identify drug resistance mechanisms and novel therapeutic targets depend greatly on the establishment of cancer drug resistant cell lines. The establishment of such drug resistant cell lines is laborious and time-consuming and various different approaches have been described. This manuscript reviews the methodologies that have been used to create cancer drug resistant cell lines and to identify their mechanisms of resistance. In addition, this review highlights the most frequent drug resistance mechanisms found in cancer cells. © 2016 Bentham Science Publishers.

Author keywords

Acquired drug resistanceAnticancer drugsCancer drug resistanceDrug resistant cancer cell linesIsogenic cell linesMechanisms of drug resistanceMultidrug resistance

Indexed keywords

EMTREE drug terms:ABC transporteraxitinibcisplatindasatinibdaunorubicinepidermal growth factor receptorepidermal growth factor receptor kinase inhibitorgefitinibimatinibnavitoclaxnilotinibolaparibpaclitaxelponatinibrociletinibruxolitinibtrastuzumabantineoplastic agent
EMTREE medical terms:acute myeloblastic leukemiaapoptosisArticleB cell lymphomacancer drug resistancecancer growthcell cyclecell cycle arrestcell survivalDNA repairdrug resistanceepithelial mesenchymal transitiongene overexpressionhumanmultidrug resistancenon small cell lung cancernonhumanpancreas cancerRNA interferencetumor celltumor microenvironmentupregulationdrug developmentdrug effectsdrug resistanceNeoplasmstumor cell culture
MeSH:Antineoplastic AgentsApoptosisDrug DiscoveryDrug Resistance, NeoplasmHumansNeoplasmsTumor Cells, Cultured

Chemicals and CAS Registry Numbers:

axitinib, 319460-85-0; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; dasatinib, 302962-49-8, 863127-77-9; daunorubicin, 12707-28-7, 20830-81-3, 23541-50-6; epidermal growth factor receptor, 79079-06-4; gefitinib, 184475-35-2, 184475-55-6, 184475-56-7; imatinib, 152459-95-5, 220127-57-1; navitoclax, 923564-51-6, 1000696-69-4, 1093851-28-5; nilotinib, 641571-10-0; olaparib, 763113-22-0; paclitaxel, 33069-62-4; ponatinib, 943319-70-8, 1114544-31-8; rociletinib, 1374640-70-6; ruxolitinib, 1092939-17-7, 941678-49-5; trastuzumab, 180288-69-1;

Antineoplastic Agents

  • ISSN: 15680096
  • CODEN: CCDTB
  • Source Type: Journal
  • Original language: English
  • PubMed ID: 26563882
  • Document Type: Article
  • Publisher: Bentham Science Publishers B.V.

  Helena Vasconcelos, M.; Cancer Drug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal;
© Copyright 2017 Elsevier B.V., All rights reserved.

Cited by 6 documents

Yao, T. , Cao, R. , Xiao, W.
An optical study of drug resistance detection in endometrial cancer cells by dynamic and quantitative phase imaging
(2019) Journal of Biophotonics
Abu, N. , Hon, K.W. , Jeyaraman, S.
Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer
(2019) Epigenomics
Lv, W. , Zhang, M. , Zhu, J.
Exploration of drug-response mechanism by integrating genetics and epigenetics across cancers
(2018) Epigenomics
View details of all 6 citations
Inform me when this document is cited in Scopus:
Set citation alert Set citation feed
{"topic":{"name":"Public Health; Education; Government","id":87407,"uri":"Topic/87407","prominencePercentile":5.858531,"prominencePercentileString":"5.859","overallScholarlyOutput":0},"dig":"b946ed3d26ea0d5972292b526c97ec938cbbecf9576040f4499cdf7c94897151"}

SciVal Topic Prominence

Topic:
Prominence percentile: